Voyager Therapeutics (VYGR) Cash from Financing Activities (2014 - 2026)

Voyager Therapeutics (VYGR) has 13 years of Cash from Financing Activities data on file, last reported at $3.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 3963.41% year-over-year to $3.3 million; the trailing twelve-month figure through Mar 2026 stood at $4.1 million (up 227.64% YoY), and the FY2025 full-year result was $816000.0, down 99.28% from the prior year.
• Cash from Financing Activities grew to $3.3 million in Q1 2026, from $136000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $112.9 million in Q1 2024 to a low of $12000.0 in Q1 2022.
• A 5-year average of $9.0 million and a median of $460000.0 in 2023 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities jumped 260783.33% in 2023 and sank 99.93% in 2025, its largest moves.
• Tracing VYGR's Cash from Financing Activities over 5 years: stood at $276000.0 in 2022, then soared by 66.67% to $460000.0 in 2023, then gained by 24.78% to $574000.0 in 2024, then sank by 76.31% to $136000.0 in 2025, then soared by 2350.0% to $3.3 million in 2026.
• Business Quant data shows VYGR's Cash from Financing Activities at $3.3 million in Q1 2026, $136000.0 in Q4 2025, and $85000.0 in Q3 2025.